566 related articles for article (PubMed ID: 17826043)
1. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
Mazzone T
Am J Med; 2007 Sep; 120(9 Suppl 2):S26-32. PubMed ID: 17826043
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
3. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control.
Schneider CA
Curr Med Res Opin; 2006; 22 Suppl 2():S15-26. PubMed ID: 16914072
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
5. Type 2 diabetes mellitus: prevention of macrovascular complications.
Meeuwisse-Pasterkamp SH; van der Klauw MM; Wolffenbuttel BH
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):323-41. PubMed ID: 18327994
[TBL] [Abstract][Full Text] [Related]
6. Prevention of coronary heart disease in type 2 diabetes.
Mykkänen L
Int J Clin Pract Suppl; 2000 Oct; (113):40-5. PubMed ID: 11965831
[TBL] [Abstract][Full Text] [Related]
7. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
Fonseca VA
Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Jones PH
Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
[TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
10. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
11. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Steinmetz A
Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
[TBL] [Abstract][Full Text] [Related]
12. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
13. [Challenge in diabetes therapy: effects of glitazones beyond blood glucose control].
Schernthaner G; Forst T; Gulba D; Haberbosch W; Hanefeld M; Linss G; März W; Mehnert H; Rosak C; Schnell O; Seufert J; Tschöpe D; Erdmann E
Dtsch Med Wochenschr; 2009 Apr; 134(18):949-54. PubMed ID: 19384816
[TBL] [Abstract][Full Text] [Related]
14. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
Wilcox R; Kupfer S; Erdmann E;
Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
[TBL] [Abstract][Full Text] [Related]
15. [Type 2 diabetes mellitus and cardiovascular diseases: evaluation, treatment and prevention strategies].
Mosseri MM; Fisman EZ; Tenenbaum A
Harefuah; 2006 Feb; 145(2):141-6, 164. PubMed ID: 16509421
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular manifestations of insulin resistance.
Chahwala V; Arora R
Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
[TBL] [Abstract][Full Text] [Related]
17. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease.
Ragucci E; Zonszein J; Frishman WH
Heart Dis; 2003; 5(1):18-33. PubMed ID: 12549986
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]